- In full:
- Robert Joseph Lefkowitz
- Born:
- April 15, 1943, Bronx, New York, U.S. (age 83)
- Awards And Honors:
- Nobel Prize (2012)
- Subjects Of Study:
- G protein-coupled receptor
- beta-adrenoreceptor
Robert J. Lefkowitz
-
Who is Robert J. Lefkowitz?
Robert J. Lefkowitz, born April 15, 1943, is an American physician and molecular biologist renowned for his work on receptors, particularly G protein-coupled receptors (GPCRs). His research revolutionized the understanding of how cells respond to stimuli like hormones and how drugs act, significantly advancing drug development.
Lefkowitz's notable discoveries include identifying beta-adrenergic receptor kinase (beta-ARK) and beta-arrestin, which regulate GPCR activity and cause GPCR desensitization. In 2012, he shared the Nobel Prize for Chemistry with Brian K. Kobilka for his groundbreaking discoveries. He also received the 2007 Shaw Prize in Life Science and Medicine and the 2007 National Medal of Science.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What field of science does Robert J. Lefkowitz work in?
Robert J. Lefkowitz is an American physician and molecular biologist known for his work on receptors, specifically G protein-coupled receptors (GPCRs), which revolutionized understanding of how cells respond to stimuli like hormones and how drugs act. His work has led to major advances in drug development. In 2012, he shared the Nobel Prize in Chemistry with Brian K. Kobilka for his groundbreaking discoveries. Lefkowitz's work primarily falls within the fields of molecular biology and biochemistry.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is Robert J. Lefkowitz best known for?
Robert J. Lefkowitz is best known for his groundbreaking discoveries related to cell receptors, specifically G protein-coupled receptors (GPCRs). His work revolutionized the understanding of how cells respond to stimuli like hormones and how certain drugs work, leading to significant advances in drug development. In the 1970s, Lefkowitz demonstrated the existence of GPCRs. For these discoveries, he shared the 2012 Nobel Prize in Chemistry with Brian K. Kobilka.
5 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What are G protein-coupled receptors, the topic of Lefkowitz's research?
Robert J. Lefkowitz was an American physician and molecular biologist who demonstrated the existence of G protein-coupled receptors (GPCRs), or receptors, which revolutionized how scientists understand cells respond to stimuli and how certain drugs work.
GPCRs are proteins in the cell membrane that bind extracellular substances and transmit signals to G proteins. There are roughly 1,000 types encoded by the human genome, responding to various substances like light, hormones, and neurotransmitters. When a GPCR binds to a ligand, it triggers a change that activates the G protein, initiating intracellular reactions that generate effects such as increased heart rate or changes in vision. Lefkowitz's work has led to major advances in drug development.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How did Lefkowitz's discoveries impact the development of new medicines?
Robert J. Lefkowitz's work on cell-surface receptors, especially G protein-coupled receptors (GPCRs), has transformed how scientists understand cell responses to stimuli like hormones and drug actions. His discoveries have significantly propelled drug development by providing insights into how drugs interact with cells. Because GPCRs play specific roles in human disease, they have provided useful targets for drug development. For instance, drugs like salmeterol and albuterol activate beta-adrenergic GPCRs to open airways, aiding in treating respiratory conditions like asthma and chronic obstructive pulmonary disease.
2 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What major awards has Robert J. Lefkowitz received for his scientific contributions?
Robert J. Lefkowitz, an American physician and molecular biologist, is renowned for his work on cell-surface receptors, particularly G protein-coupled receptors (GPCRs). His discoveries have significantly advanced the understanding of cellular responses to stimuli like hormones and drug actions.
Lefkowitz's major awards include:
* 2012 Nobel Prize for Chemistry
* 2007 Shaw Prize in Life Science and Medicine
* 2007 National Medal of ScienceHe was also elected a member of the National Academy of Sciences (1988) and the American Academy of Arts and Sciences.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.
Robert J. Lefkowitz (born April 15, 1943, Bronx, New York, U.S.) is an American physician and molecular biologist who demonstrated the existence of receptorsâmolecules that receive and transmit signals for cells. His research on the structure and function of cell-surface receptorsâparticularly of G protein-coupled receptors (GPCRs), the largest family of signal-receiving molecules found in organismsârevolutionized scientistsâ understanding of how cells respond to stimuli such as hormones and how certain types of drugs exert their actions, leading to major advances in drug development. For his groundbreaking discoveries, Lefkowitz shared the 2012 Nobel Prize for Chemistry with American physician and molecular biologist Brian K. Kobilka.
In 1959 Lefkowitz graduated from the Bronx High School of Science. He received a scholarship to study at Columbia College, Columbia University, New York, where he earned a B.A. in chemistry in 1962. Having decided at an early age that he wanted to be a physician, he remained in New York to study at the Columbia University College of Physicians and Surgeons, receiving an M.D. in 1966. Two years later, after a residency at Columbia, he took a position at the National Institute of Arthritis and Metabolic Diseases (NIAMD; later the National Institute of Diabetes and Digestive and Kidney Diseases), part of the National Institutes of Health in Maryland, where he set to work on validating the existence of receptors. His initial research focused on developing a procedure (an assay) by which radioactively labeled adrenocorticotropic hormone (ACTH) would bind specifically to the membranes of cancer cells; such an assay would facilitate the purification of receptors. By 1970 he had successfully developed the procedure and had published evidence for the existence of cell-surface receptors. That year he left NIAMD for a residency and training in cardiovascular disease at Massachusetts General Hospital in Boston. In 1972, while working in the laboratory of German American physician and researcher Edgar Haber, he published a report detailing his purification of beta-adrenergic receptor protein from heart muscle cells (cardiomyocytes) in dogs. The beta-adrenergic receptor would later become a model system for the study of GPCRs.
In 1973 Lefkowitz joined the faculty at the Duke University Medical Center in Durham, North Carolina, where he later found that adrenergic receptors transmit signals to an intracellular molecule called a G protein (guanine nucleotide-binding protein), which had been discovered earlier by American pharmacologist Alfred G. Gilman and American biochemist Martin Rodbell (Gilman and Rodbell shared the 1994 Nobel Prize for Physiology or Medicine for their independent discovery of G proteins). When activated, G proteins stimulate an enzyme known as adenylate cyclase, which converts the energy-carrying molecule ATP (adenosine triphosphate) to cAMP (cyclic adenosine monophosphate), a process responsible for producing physiological responses prompted by hormone-receptor binding. Lefkowitz also discovered a molecule known as beta-adrenergic receptor kinase (beta-ARK), which regulates GPCR activity.
In 1984 Kobilka joined Lefkowitzâs research group at Duke. Lefkowitz was then trying to determine the DNA sequence of the beta2-adrenergic receptor. Kobilka proceeded to piece together the DNA sequence using bacteria that had been genetically engineered to produce large quantities of genomic DNA, thereby overcoming the limitations imposed by the receptorâs restricted natural production in cells. Kobilkaâs breakthrough facilitated the teamâs discovery that all GPCRs possess seven domains that cross through the cell membrane; those domains were found to be fundamental to the receptorsâ activity. Lefkowitz later identified a protein called beta-arrestin, which acts on beta-ARK-phosphorylated GPCRs and which explained the phenomenon of GPCR desensitization in response to repeated agonist binding.
In addition to the 2012 Nobel Prize, Lefkowitz was the recipient of several other major awards, including the 2007 Shaw Prize in Life Science and Medicine and the 2007 National Medal of Science, presented to him by U.S. Pres. George W. Bush. In 1988 Lefkowitz was elected a member of the National Academy of Sciences and the American Academy of Arts and Sciences.